Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Net Income towards Common Stockholders (2023 - 2025)

Historic Net Income towards Common Stockholders for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$27.1 million.

  • Monte Rosa Therapeutics' Net Income towards Common Stockholders fell 1350.43% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 11751.67%. This contributed to the annual value of -$72.7 million for FY2024, which is 4626.6% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' Net Income towards Common Stockholders stood at -$27.1 million, which was down 1350.43% from -$12.3 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $46.9 million during Q1 2025, with a 5-year trough of -$35.2 million in Q2 2023.
  • Over the past 3 years, Monte Rosa Therapeutics' median Net Income towards Common Stockholders value was -$30.3 million (recorded in 2024), while the average stood at -$18.2 million.
  • Examining YoY changes over the last 5 years, Monte Rosa Therapeutics' Net Income towards Common Stockholders showed a top increase of 24658.43% in 2025 and a maximum decrease of 1350.43% in 2025.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Net Income towards Common Stockholders stood at -$33.3 million in 2023, then surged by 140.32% to $13.4 million in 2024, then tumbled by 301.99% to -$27.1 million in 2025.
  • Its last three reported values are -$27.1 million in Q3 2025, -$12.3 million for Q2 2025, and $46.9 million during Q1 2025.